2018-10-26 16:00Financial Performance - Net profit attributable to shareholders rose by 22.96% to CNY 99,268,432.76 for the reporting period[7] - Operating revenue for the period reached CNY 561,675,754.45, reflecting a 30.09% increase year-on-year[7] - Basic earnings per share increased by 22.99% to CNY 0.1985 for the reporting period[7] - The weighted average return on equity improved to 3.89%, a 25.15% increase compared to the previous year[7] - The net profit attributable to shareholders for the year-to-date period increased by 58.67% to CNY 317,921,570.96[7] - The company reported a total comprehensive income of ¥118,063,367.91, up from ¥87,397,671.51, which is an increase of approximately 35.0%[65] - Net profit for the current period was ¥108,274,329.77, compared to ¥91,169,438.57 in the previous period, reflecting an increase of approximately 18.8%[64] - The company reported a net profit of ¥40,911,186.60 for the current quarter, down from ¥100,666,491.69 in the previous quarter, indicating a decline of approximately 59.5%[69] Assets and Liabilities - Total assets increased by 13.81% to CNY 4,077,889,908.87 compared to the end of the previous year[7] - Total liabilities rose to CNY 938,324,911.74 from CNY 781,854,449.47, marking an increase of approximately 19.9%[57] - Current assets rose to CNY 1,444,173,659.49, up from CNY 1,345,590,415.39, indicating an increase of about 7.3%[55] - Accounts receivable increased significantly to CNY 775,295,134.00 from CNY 631,686,778.14, reflecting a growth of approximately 22.7%[55] - The long-term equity investment increased to CNY 95,674,462.29 from CNY 90,459,877.27, a growth of approximately 5.3%[56] Cash Flow - The net cash flow from operating activities increased by 148.39% to CNY 344,471,128.31 year-to-date[7] - Cash flow from operating activities amounted to CNY 344.47 million, significantly higher than CNY 138.68 million in the same period last year, marking an increase of 148.5%[77] - Net cash flow from investment activities was -¥34,998.54 million, with cash inflow of ¥43,438.58 million primarily from equity transfer payments[31] - The net cash flow from financing activities was -¥3,366.04 million, with cash inflow of ¥20,277.04 million mainly from borrowings[32] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 13,657[11] - Major shareholder Ye Xiaoping holds 24.82% of the shares, with 100,592,050 shares pledged[11] - The company plans to distribute a cash dividend of 2 RMB per 10 shares, totaling 100,035,307.40 RMB, based on a total share capital of 500,176,537 shares as of December 31, 2017[47] Research and Development - R&D expenses grew by 71.95% year-on-year to ¥75,004,040.65, attributed to an increase in R&D personnel and projects[26][28] - Research and development expenses increased to ¥24,308,021.12 from ¥16,380,879.91, marking a growth of about 48.5%[63] Strategic Initiatives - The company plans to establish a healthcare industry merger fund in collaboration with Yunnan Watson Biotechnology Co., Ltd.[33] - The company intends to invest ¥20 million in a pharmaceutical industry merger fund with Zhejiang Jiuzhou Pharmaceutical Co., Ltd. and Zhongyu Capital Management[37] - The company has initiated preparations for the spin-off and listing of its subsidiary, Frontage Holdings Corporation, on the Hong Kong Stock Exchange, following the approval from the annual shareholders' meeting in 2017[39] - The company announced a strategic cooperation agreement with Zhejiang Jiuzhou Pharmaceutical Co., Ltd.[43] Financial Management - The company has implemented a cash dividend policy as approved in the 2017 annual shareholders' meeting[46] - There were no violations of external guarantees during the reporting period[48] - The company has fulfilled all commitments made to minority shareholders in a timely manner[45] - The company has not engaged in any related party transactions that would constitute competition with its business[45]